Latest Commercial Launch News

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Peppermint Innovation Ltd reported robust growth in its Philippines digital payments platform during Q4 2025, with wallet prefunding surpassing PHP 486 million and transaction volumes surging. The company is preparing to launch a new payment processing business in March 2026 while actively pursuing capital raising to support expansion.

Unith Ltd reports a 17% rise in quarterly cash receipts alongside strategic funding and new technology launches, signalling momentum in its AI-driven digital human platform.

FlexiRoam has reported its second consecutive quarter of positive operating cash flow and returned to a positive net current asset position for the first time in over eight years, underpinned by record underlying EBITDA and strategic AI partnerships.

Micro-X Ltd has secured a historic $3.3 million order for its Rover mobile X-ray units in Malaysia, alongside a $6.2 million capital raise to fuel its expanding medical imaging and security technology pipeline.

Knosys reports steady revenue growth and a strategic partnership to upgrade its GreenOrbit platform, while accelerating development of its AI-powered Libero X library solution for a global launch next year.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

Anteris Technologies has closed a $320 million capital raise, combining a $230 million public offering and a strategic private placement with Medtronic, to advance its DurAVR heart valve clinical trials and manufacturing growth.

LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.